ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,168.96
0.30%
Dow Jones
37,815.92
-1.49%
Gold vs US Dollar
2,286.43
-0.23%
Brent Oil
85.30
-0.69%
Bitcoin
57,026.36
-5.90%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Agenus Inc (AGEN)

  7. Agenus Inc (AGEN) News

Agenus (AGEN)

Agenus Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AGEN
DateTimeSourceHeadlineSymbolCompany
24/04/202415:00Business WireBotensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual MeetingNASDAQ:AGENAgenus Inc
23/04/202412:30Business WireAgenus to Provide First Quarter 2024 Financial Report and Corporate UpdateNASDAQ:AGENAgenus Inc
12/04/202412:30Business WireAgenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal CancerNASDAQ:AGENAgenus Inc
05/04/202421:30Business WireAgenus Announces Reverse Stock Split of Common StockNASDAQ:AGENAgenus Inc
14/03/202411:30Business WireAgenus Reports Fourth Quarter and Full Year 2023 ResultsNASDAQ:AGENAgenus Inc
06/03/202412:30Business WireAgenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024NASDAQ:AGENAgenus Inc
05/03/202421:30Business WireAgenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:AGENAgenus Inc
29/02/202421:50Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AGENAgenus Inc
29/02/202412:30Business WireAgenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial ReportNASDAQ:AGENAgenus Inc
26/02/202421:24Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:AGENAgenus Inc
26/02/202412:30Business WireAgenus to Participate in Leerink Partners Global Biopharma ConferenceNASDAQ:AGENAgenus Inc
15/02/202413:02Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:AGENAgenus Inc
15/02/202413:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
15/02/202412:02PR Newswire (US)Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular DesignNASDAQ:AGENAgenus Inc
14/02/202413:33Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AGENAgenus Inc
12/02/202412:00Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
12/02/202412:00Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
09/02/202422:11Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AGENAgenus Inc
31/01/202413:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
31/01/202412:30Business WireAgenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:AGENAgenus Inc
22/01/202414:59Business WireBotensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer PopulationNASDAQ:AGENAgenus Inc
22/01/202412:30Business WireBotensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer PopulationNASDAQ:AGENAgenus Inc
05/01/202421:30Business WireAgenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:AGENAgenus Inc
04/01/202412:30Business WireAgenus to Participate in B. Riley Healthcare ConferenceNASDAQ:AGENAgenus Inc
04/01/202411:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
04/01/202411:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
04/01/202411:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
20/12/202312:30Business WireBotensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024NASDAQ:AGENAgenus Inc
11/12/202312:30Business WireAgenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific ProgramNASDAQ:AGENAgenus Inc
08/12/202321:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
 Showing the most relevant articles for your search:NASDAQ:AGEN

Your Recent History

LSE
SYME
Supply@me Capital
LSE
MIN
Minoan
LSE
TXP
Touchstone Exploration
LSE
TRIN
Trinity Exploration & Pr...
LSE
AAU
Ariana Resources
LSE
GFM
Griffin Mining
LSE
TERN
Tern
LSE
AAZ
Anglo Asian Mining
LSE
GSF
Gore Street Energy Storage
LSE
PANR
Pantheon Resources
LSE
SCLP
Scancell
LSE
BIRD
Blackbird
LSE
ALGW
Alpha Growth
LSE
POS
Plexus
LSE
GCM
Gcm Resources
LSE
GGP
Greatland Gold
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved